1236-P: Patients with Diabetes Mellitus and Chronic Kidney Disease Affected by Nonalcoholic Fatty Liver Disease Have Greater Risk of Mortality and Worse Clinical Outcomes
Background: DM & CKD are affecting million patients worldwide. Nonalcoholic Fatty Liver Disease (NAFLD) is emerging disease predisposing to adverse outcomes. There is limited evidence of clinical outcomes of NAFLD in patients with DM&CKD. We sought to investigate this population. Methods: We...
Saved in:
Published in | Diabetes (New York, N.Y.) Vol. 72; no. Supplement_1; p. 1 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
New York
American Diabetes Association
20.06.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: DM & CKD are affecting million patients worldwide. Nonalcoholic Fatty Liver Disease (NAFLD) is emerging disease predisposing to adverse outcomes. There is limited evidence of clinical outcomes of NAFLD in patients with DM&CKD. We sought to investigate this population.
Methods: We queried NIS 2017-2020 for adults hospitalized with DM&CKD & NAFLD. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, GIB, intubation, LOS & total hospital charge. Multivariable logistic regression analysis was used to estimate clinical outcomes.
Results: There were 11,254,722 hospitalizations with DM&CKD and 542,140 (4.8%) had NAFLD. NAFLD & non-NAFLD cohorts were with mean age of 53.3 vs. 54.0 yrs; males 53.3% vs 54.0%; Caucasians 58.7% vs 57.7%; HF 49.4% vs 49.5%; PH 11.4% vs 9.0%; AKI 51.9% vs 43.7%; obesity 24.9% vs 27.0%; HLD 47.0% vs 61.1%; anemia 23.6% vs 20.1%; ACS 10.6% vs 10.3%; stroke 1.8% vs 3.0%, respectively.
Conclusion: DM&CKD cohort showed significantly higher mortality, worse clinical outcomes & resource utilization (Table 1). They were younger, obese, female, Caucasian, & with more PH, AKI, anemia, ACS. NAFLD is associated with greater risk for MACE, GIB, & ICU care. NALFD is an important risk factor among patients with DM&CKD that predicts adverse outcomes.
Disclosure
L. Khokhlov: None. U. Thapa: None. L. Pereira: None. M. Fatuyi: None. M. Ali: None. F. Hussain: None. A. Aboelnasr: None. A.C. Brown: None. M. Eerhart: None. M. Eshghabadi: None. C. Contreras: None. K. Shemisa: Speaker's Bureau; Pfizer Inc., Boehringer Ingelheim (Canada) Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Amarin Corporation, Bayer Inc. |
---|---|
AbstractList | Background: DM & CKD are affecting million patients worldwide. Nonalcoholic Fatty Liver Disease (NAFLD) is emerging disease predisposing to adverse outcomes. There is limited evidence of clinical outcomes of NAFLD in patients with DM&CKD. We sought to investigate this population.
Methods: We queried NIS 2017-2020 for adults hospitalized with DM&CKD & NAFLD. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, GIB, intubation, LOS & total hospital charge. Multivariable logistic regression analysis was used to estimate clinical outcomes.
Results: There were 11,254,722 hospitalizations with DM&CKD and 542,140 (4.8%) had NAFLD. NAFLD & non-NAFLD cohorts were with mean age of 53.3 vs. 54.0 yrs; males 53.3% vs 54.0%; Caucasians 58.7% vs 57.7%; HF 49.4% vs 49.5%; PH 11.4% vs 9.0%; AKI 51.9% vs 43.7%; obesity 24.9% vs 27.0%; HLD 47.0% vs 61.1%; anemia 23.6% vs 20.1%; ACS 10.6% vs 10.3%; stroke 1.8% vs 3.0%, respectively.
Conclusion: DM&CKD cohort showed significantly higher mortality, worse clinical outcomes & resource utilization (Table 1). They were younger, obese, female, Caucasian, & with more PH, AKI, anemia, ACS. NAFLD is associated with greater risk for MACE, GIB, & ICU care. NALFD is an important risk factor among patients with DM&CKD that predicts adverse outcomes.
Disclosure
L. Khokhlov: None. U. Thapa: None. L. Pereira: None. M. Fatuyi: None. M. Ali: None. F. Hussain: None. A. Aboelnasr: None. A.C. Brown: None. M. Eerhart: None. M. Eshghabadi: None. C. Contreras: None. K. Shemisa: Speaker's Bureau; Pfizer Inc., Boehringer Ingelheim (Canada) Ltd., Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Amarin Corporation, Bayer Inc. Background: DM & CKD are affecting million patients worldwide. Nonalcoholic Fatty Liver Disease (NAFLD) is emerging disease predisposing to adverse outcomes. There is limited evidence of clinical outcomes of NAFLD in patients with DM&CKD. We sought to investigate this population. Methods: We queried NIS 2017-2020 for adults hospitalized with DM&CKD & NAFLD. The primary outcome was inpatient mortality. The secondary outcomes were cardiogenic shock, cardiac arrest, GIB, intubation, LOS & total hospital charge. Multivariable logistic regression analysis was used to estimate clinical outcomes. Results: There were 11,254,722 hospitalizations with DM&CKD and 542,140 (4.8%) had NAFLD. NAFLD & non-NAFLD cohorts were with mean age of 53.3 vs. 54.0 yrs; males 53.3% vs 54.0%; Caucasians 58.7% vs 57.7%; HF 49.4% vs 49.5%; PH 11.4% vs 9.0%; AKI 51.9% vs 43.7%; obesity 24.9% vs 27.0%; HLD 47.0% vs 61.1%; anemia 23.6% vs 20.1%; ACS 10.6% vs 10.3%; stroke 1.8% vs 3.0%, respectively. Conclusion: DM&CKD cohort showed significantly higher mortality, worse clinical outcomes & resource utilization (Table 1). They were younger, obese, female, Caucasian, & with more PH, AKI, anemia, ACS. NAFLD is associated with greater risk for MACE, GIB, & ICU care. NALFD is an important risk factor among patients with DM&CKD that predicts adverse outcomes. |
Author | BROWN, AMANDA C. ABDULRAHMAN HUSSAIN, FATIMA AMIN ESHGHABADI, MOHAMMAD PEREIRA, LEANNE CONTRERAS, CYNTHIA ALI, MEHNAAZ ABOELNASR, AMR THAPA, USHA EERHART, MICHAEL SHEMISA, KAMAL KHOKHLOV, LEONID FATUYI, MICHAEL |
Author_xml | – sequence: 1 givenname: LEONID surname: KHOKHLOV fullname: KHOKHLOV, LEONID – sequence: 2 givenname: USHA surname: THAPA fullname: THAPA, USHA – sequence: 3 givenname: LEANNE surname: PEREIRA fullname: PEREIRA, LEANNE – sequence: 4 givenname: MICHAEL surname: FATUYI fullname: FATUYI, MICHAEL – sequence: 5 givenname: MEHNAAZ surname: ALI fullname: ALI, MEHNAAZ – sequence: 6 givenname: FATIMA surname: ABDULRAHMAN HUSSAIN fullname: ABDULRAHMAN HUSSAIN, FATIMA – sequence: 7 givenname: AMR surname: ABOELNASR fullname: ABOELNASR, AMR – sequence: 8 givenname: AMANDA C. surname: BROWN fullname: BROWN, AMANDA C. – sequence: 9 givenname: MICHAEL surname: EERHART fullname: EERHART, MICHAEL – sequence: 10 givenname: MOHAMMAD surname: AMIN ESHGHABADI fullname: AMIN ESHGHABADI, MOHAMMAD – sequence: 11 givenname: CYNTHIA surname: CONTRERAS fullname: CONTRERAS, CYNTHIA – sequence: 12 givenname: KAMAL surname: SHEMISA fullname: SHEMISA, KAMAL |
BookMark | eNo90d9KwzAUBvAgCs7plS8Q8FKq-VPbxbsxdRM3HSLoXUmTExbtGk1Spa_kU5o5kVwEwo_zkfMdoN3WtYDQMSVnjPPyXNeMZ5TxIlvuoAEVXGSclS-7aEAIZRktRbmPDkJ4JYQU6QzQ91Zf4qWMFtoY8JeNK3xlZQ0RAl5A09jYBSxbjScr71qr8J3VLfQJBZAB8NgYUBE0rnt871rZKLdyTXI3MsYez-0n-H88k5-Apx5kTI-PNrxhZ_DC-ShTTv8b8-x8gpPGpizZ4IcuKreGcIj2jGwCHP3dQ_R0c_00mWXzh-ntZDzPVJHnWamKkeJGckoNBQWFMcLkXBClC5XrHLTMk6mNEIITrpQ0SZuaXBjNRprxITrZjn337qODEKtX1_n0q1CxUS74hWAsT-p0q5R3IXgw1bu3a-n7ipJq00W16aLabLda8h_mh4CV |
ContentType | Journal Article |
Copyright | Copyright American Diabetes Association Jun 2023 |
Copyright_xml | – notice: Copyright American Diabetes Association Jun 2023 |
DBID | AAYXX CITATION K9. NAPCQ |
DOI | 10.2337/db23-1236-P |
DatabaseName | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitle | CrossRef ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Premium |
DatabaseTitleList | CrossRef ProQuest Health & Medical Complete (Alumni) |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1939-327X |
ExternalDocumentID | 10_2337_db23_1236_P |
Genre | Conference Proceeding |
GroupedDBID | --- .55 .XZ 08P 0R~ 18M 29F 2WC 354 4.4 53G 5GY 5RE 5RS 5VS 6PF 8R4 8R5 AAQQT AAWTL AAYEP AAYXX ABOCM ACGFO ACGOD ACPRK ADBBV AEGXH AENEX AERZD AFHIN AHMBA AIAGR AIZAD ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BES BTFSW CITATION CS3 DIK DU5 E3Z EBS EDB EMOBN EX3 F5P FRP GX1 HZ~ IAO IEA IHR INH INR IOF IPO K2M KQ8 L7B M5~ O5R O5S O9- OHH OK1 OVD P2P PCD Q2X RHF RHI RPM SJN SV3 TDI TEORI TR2 VVN W8F WH7 WOQ WOW X7M YFH YHG YOC ZY1 ~KM K9. NAPCQ |
ID | FETCH-LOGICAL-c644-7c68c3fa311f1ece6ff9f4390cd6c4d4eda47c6bf999303ccaf3fafb05fd28d23 |
ISSN | 0012-1797 |
IngestDate | Thu Oct 10 16:10:49 EDT 2024 Fri Aug 23 01:06:30 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c644-7c68c3fa311f1ece6ff9f4390cd6c4d4eda47c6bf999303ccaf3fafb05fd28d23 |
PQID | 2849359224 |
PQPubID | 34443 |
ParticipantIDs | proquest_journals_2849359224 crossref_primary_10_2337_db23_1236_P |
PublicationCentury | 2000 |
PublicationDate | 2023-06-20 |
PublicationDateYYYYMMDD | 2023-06-20 |
PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-20 day: 20 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York |
PublicationTitle | Diabetes (New York, N.Y.) |
PublicationYear | 2023 |
Publisher | American Diabetes Association |
Publisher_xml | – name: American Diabetes Association |
SSID | ssj0006060 |
Score | 2.4735756 |
Snippet | Background: DM & CKD are affecting million patients worldwide. Nonalcoholic Fatty Liver Disease (NAFLD) is emerging disease predisposing to adverse outcomes.... |
SourceID | proquest crossref |
SourceType | Aggregation Database |
StartPage | 1 |
SubjectTerms | Anemia Clinical outcomes Diabetes Diabetes mellitus Fatty liver Kidney diseases Liver diseases Mortality Obesity Patients Resource utilization Risk factors |
Title | 1236-P: Patients with Diabetes Mellitus and Chronic Kidney Disease Affected by Nonalcoholic Fatty Liver Disease Have Greater Risk of Mortality and Worse Clinical Outcomes |
URI | https://www.proquest.com/docview/2849359224 |
Volume | 72 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiFxQDzFwoLmsDcUyKNpE26rLVWh21JBV_QWxbGtVosa1E2Qlp_ED-F3MeNHkq1WCLhElWM5Tubr-PN4Howdx4kQuJJxL5YxblCkrzweC-4VSe6nvl9wJSl2eDYfTM77H1bxqtf71fFaqiv-uvhxY1zJ_0gV21CuFCX7D5JtBsUG_I3yxStKGK9_JWPKaeItaFO_MOlRbazayBlUZ5Rus6pNHmabB_fVdCO2qAlG5miGznRQ6RkiOidermvmYr9xXiFDPyPHjabzhIoVabMCNn6ybukzTeGJztNjvpQ77HjqIi4_1hW-uvVUtCx41DH47pcC6pgmpuvyYv21_K5tBxLnLlo3Flzjqfn8cp232n0nN7psEmWN3bb-Avgi9dVmP0jAmjpCKjvhhX4LTneG1cxyH8JWyQchZV0167g0ej2NUi8Kh6uu4jc1g6zmDm5aT8JIZyQQHOdiRNoum85VYHLyOVuMxtnZ-_n0FrsdDtM4dlYjywhwk2hCoezETJwoDf6mM_R1ZnSdGGi2s7zP7tltCpwYzD1gPbl9yO7MrCPGI_bTDPYWHPCAgAfuk4EDHiAiwAIPDPDAYgkc8IBfQRd4oIEHGnhNZwIeWOABAQ9KBQ3w9GM08MABDxzwHrPl-N3ydOLZsh9egeTcGxaDpIhUHgWBCmQhB0qlCmmzX4hB0Rd9KfI-9uEKtzbIv1ADKeytuB8rESYijJ6wg225lU8ZyIQrXySyyDmy2IDneZrKiKshDwPk2cEhO3ZfPPtmkrtkuCkmwWQkmIy-ZbY4ZEdOGpn9919mSOsoqB0Z8LM_337O7oYtmI_YQbWr5QtkshV_qWHyGzC9pRk |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=1236-P%3A+Patients+with+Diabetes+Mellitus+and+Chronic+Kidney+Disease+Affected+by+Nonalcoholic+Fatty+Liver+Disease+Have+Greater+Risk+of+Mortality+and+Worse+Clinical+Outcomes&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=Khokhlov%2C+Leonid&rft.au=Thapa%2C+Usha&rft.au=Pereira%2C+Leanne&rft.au=Fatuyi%2C+Michael&rft.date=2023-06-20&rft.pub=American+Diabetes+Association&rft.issn=0012-1797&rft.eissn=1939-327X&rft.volume=72&rft.spage=1&rft_id=info:doi/10.2337%2Fdb23-1236-P&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon |